Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Lansoprazole, a substituted benzimidazole, functions as a proton pump inhibitor by targeting H+,K(+)-adenosine triphosphatase in parietal cells.
• It demonstrates potent inhibition of gastric acid secretion, similar to the established proton pump inhibitor, omeprazole.

Purpose of the Study:

• To compare the efficacy and safety of lansoprazole versus omeprazole in patients with active duodenal ulcers.

Main Methods:

• A double-blind, randomized comparative study involving 279 patients with active duodenal ulcers.
• Participants were treated with either 30 mg of lansoprazole or 20 mg of omeprazole, administered in the morning.
• Demographic data were comparable between the two treatment groups.

Main Results:

• No significant difference in healing rates was observed between lansoprazole and omeprazole groups at 2 weeks (86.2% vs. 82.1%) or 4 weeks (97.1% vs. 96.2%).
• Both treatments resulted in high healing rates for active duodenal ulcers.
• No patients discontinued treatment due to adverse side effects.

Conclusions:

• Lansoprazole and omeprazole are equally effective in achieving high healing rates and providing symptom relief for active duodenal ulcers.
• Both proton pump inhibitors are well-tolerated, with few and mild side effects reported.